No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
JELD240517P15000
- 0.55
- -0.03-5.17%
15min DelayClose May 15 15:59 ET
0.55High0.55Low
0.55Open0.58Pre Close1 Volume212 Open Interest15.00Strike Price55.00Turnover119.69%IV-5.55%PremiumMay 17, 2024Expiry Date0.00Intrinsic Value100Multiplier1DDays to Expiry0.55Time Value100Contract SizeAmericanOptions Type-0.3089Delta0.2656Gamma56.69Leverage Ratio-0.1434Theta-0.0002Rho-17.51Eff Leverage0.0039Vega
Intraday
- 5D
- 1D
News
B. Riley Adjusts Price Target on JELD-WEN to $17 From $20, Keeps Neutral Rating
JELD-WEN Holding (JELD) has an average rating of hold and price targets ranging from $12 to $24, according to analysts polled by Capital IQ. Price: 14.75, Change: -0.07, Percent Change: -0.47
Express News | JELD-WEN Holding Inc : Jefferies Cuts Target Price to $16 From $20
JELD-WEN Is Maintained at Equal-Weight by Barclays
JELD-WEN Is Maintained at Equal-Weight by Barclays
Express News | Barclays Maintains Equal-Weight on JELD-WEN Holding, Lowers Price Target to $15
Barclays Sticks to Their Hold Rating for JELD-WEN (JELD)
Express News | JELD-WEN Holding Inc : Barclays Cuts Target Price to $15 From $18
Comments
The trend of lower returns on the same capital suggests it's not a growth stock. The declining ROCE and stagnant capital employed could indicate a mature business facing new competition or smaller margins.
The Returns On Capital At JELD-WEN Holding (NYSE:JELD) Don't Inspire Confidence 1
Insider selling at JELD-WEN Holding, even below the current price, may worry investors. The absence of insider buying in the past year doesn't convey optimism about the stock. Yet, moderate insider ownership shows some alignment between management and smaller shareholders.
JELD-WEN's ROE is below industry average and its high debt levels could signal risk. The company's reliance on debt to boost ROE is less satisfactory due to its sub-par returns.
JELD-WEN Holding's stable ROCE suggests a mature operation without promising substantial growth. The stock's 41% decline over five years questions the prospect for these trends to improve soon, making the company a less attractive option for potential multi-bagger returns.
Gapping up
In reaction to earnings/guidance:
• $ChargePoint(CHPT.US$ +2.8%, $Designer Brands(DBI.US$ +1.8%, $Donaldson(DCI.US$ +0.7%
Other news:
• $Cepton(CPTN.US$ +9.2% (receives non-bindingLolfor a $100mln investment from Koito Manufacturing)
• $Sorrento Therapeutics(SRNE.US$ +7.2% (receives FDA Fast Track Designation for SP-103(Lidocaine Topical System) 5.4%)
• $Mereo BioPharma(MREO.US$ +6.7% (sends letter to Rubric Capital...
In reaction to earnings/guidance:
• $ChargePoint(CHPT.US$ +2.8%, $Designer Brands(DBI.US$ +1.8%, $Donaldson(DCI.US$ +0.7%
Other news:
• $Cepton(CPTN.US$ +9.2% (receives non-bindingLolfor a $100mln investment from Koito Manufacturing)
• $Sorrento Therapeutics(SRNE.US$ +7.2% (receives FDA Fast Track Designation for SP-103(Lidocaine Topical System) 5.4%)
• $Mereo BioPharma(MREO.US$ +6.7% (sends letter to Rubric Capital...
9
Read more